ClinicalTrialsFinder
RecruitingPhase 1NCT07541781

Sitagliptin in Recurrent/Progressive Grade 4 Glioma

Targeting Myeloid-Derived Suppressor Cells in Patients With Recurrent/Progressive Grade 4 Glioma: Phase 1 Trial of Sitagliptin

Sponsor

Kailin Yang, MD, PhD

Enrollment

45 participants

Start Date

Jun 11, 2026

Study Type

INTERVENTIONAL

Conditions

GlioblastomaGliomaRecurrent GlioblastomaRecurrent GliomaGrade 4 Malignant Glioma of Brain (Disorder)

Summary

Sitagliptin, when combined with standard-of-care drug bevacizumab, is being tested to 1) find out if it is effective at treating gliomas that have returned or progressed after treatment, and 2) find out what the highest dose of sitagliptin is appropriate to give when combined with bevacizumab.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a biological treatment called Bevacizumab and a drug called Sitagliptin for people with glioblastoma, glioma, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGSitagliptin

Sitagliptin, PO dose to be determined by Phase I dose de-escalation, cycle length 28 days. Treatment until progression.

BIOLOGICALBevacizumab

Bevacizumab, IV, 10 mg/kg days 1 and 15 every 28 days, until progression.

Locations(1)

University of Iowa Health Care

Iowa City, Iowa, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07541781

Related Trials

REMIND Maintenance Radiotherapy for Newly Diagnosed Glioblastoma

NCT07831772

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

NCT071955916 locations

Pharmacoscopy for Patients With Refractory Primary Brain Tumors

NCT06804655

ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial

NCT070896412 locations

VISTA: Valproic Acid, Irinotecan, and Simvastatin for Recurrent Glioma

NCT07831369